与传统药物相比,植入性药物输注系统附加的综合性药物管理(comprehensive medical management ,CMM)临床效果更好。Smith等[3]进行了植入性药物输注系统附加的综合性的药物管理与单独的综合性药物治疗的200例难治性癌性疼痛的随机临床试验,结果显示在植入IDDS后,难治性疼痛的患者的疼痛评分和药物毒性评分都有明显的下降。并可能会延长患者3个月的生存时间,从而使植入性药物输注系统(IDDS)获得更高的效益。在此前瞻性研究中,难治的癌性疼痛患者不管综合的药物治疗效果如何都可以从IDDS中得到益处。
2. Grider JS, HarnedME, Etscheidt MA. Patient selection and outcomes using a low-dose intrathecalopioid trialing method for chronic nonmalignant pain. Pain Physician,2011,14(4):343-351.
3. Smith TJ, Coyne PJ.Implantable drug delivery systems (IDDS) after failure of comprehensive medicalmanagement (CMM) can palliate symptoms in the most refractory cancer pain patients.J Palliat Med, 2005 ,8(4):736-742.
4. Compoginis JM,Richeimer SH, Brody GS. Placement of an implantable drug delivery system under thebreast. Pain Med, 2007 ,8(6):521-524.
5. Duarte RV, RaphaelJH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignantpain. J Neurosurg Anesthesiol,2012,24(1):63-70.
6. Burgher AH, BarnettCF, Obray JB, et al. Introduction of infection control measures to reduceinfection associated with implantable pain therapy devices. Pain Pract, 2007, 7(3):279-284.
7. Ramsey CN, Owen RD,Witt WO, et al. Intrathecal granuloma in a patient receiving high dose hydromorphone.Pain Physician, 2008 ,11(3):369-373.
8. Vodapally MS,Thimineur MA, Mastroianni PP. Tension pseudomeningocele associated withretained intrathecal catheter: a case report with a review of literature. PainPhysician, 2008, 11(3):355-362.